Hub : Traits :

Medication: Cholesterol lowering

194 significantly associated models · 70 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	61510619	63844736	4	1	4.1e-14	2.2e-13	3.3e-01	98	DOCK7
2	1	108854166	110931112	10	1	4.3e-55	6.7e-56	1.0e+00	100	PSRC1
3	2	20529948	21958745	1	1	1.6e-28	1.1e-29	1.0e+00	100	APOB
4	2	26883355	28414302	6	1	3.7e-15	4.6e-15	1.0e+00	100	FNDC4
5	2	43791363	44450524	2	2	1.2e-09	7.1e-25	2.0e-14	45	ABCG5 LRPPRC
6	5	73969058	75594743	4	1	3.3e-14	1.5e-13	1.6e-01	96	HMGCR
7	6	159820779	161213047	2	2	3.5e-10	3.3e-18	2.2e-10	47	RP11-288H12.3 SLC22A1
8	8	18003897	18505600	1	1	1.5e-07	2.3e-07	1.8e-02	79	NAT2
9	8	19064892	20521138	1	1	1.8e-13	8.0e-14	2.7e-04	76	LPL
10	8	144294773	145744618	1	1	9.8e-08	3.8e-07	6.0e-01	99	PLEC
11	9	135883620	136399075	1	1	1.3e-10	6.1e-09	2.0e-02	84	ABO
12	11	100168289	101559718	1	1	9.0e-08	1.2e-06	6.7e-01	99	TMEM133
13	11	115953897	117800682	5	3	5.4e-23	3.4e-24	8.2e-01	100	BUD13 PAFAH1B2 ZNF259
14	11	125979757	126556323	1	1	2.1e-07	1.4e-05	2.0e-01	91	ST3GAL4
15	15	90730363	92135418	1	1	8.9e-10	2.2e-08	6.9e-01	100	FES
16	16	71349498	72845749	5	2	1.1e-10	3.2e-10	1.0e+00	100	DHX38 HP
17	19	10016470	12191233	7	4	5.8e-18	3.6e-51	7.9e-19	65	C19orf80 EPOR LDLR SLC44A2
18	19	18740208	20451172	6	1	8.3e-14	9.5e-18	7.2e-06	73	ATP13A1
19	19	44235517	46098885	5	5	3.4e-12	2.8e-62	1.8e-37	41	APOC2 BCAM PVRL2 TOMM40 ZNF229
20	19	48464978	49872085	2	1	6.9e-08	4.7e-08	1.0e+00	100	FUT2
21	20	62008975	62912463	3	1	1.1e-09	1.8e-08	7.8e-01	100	OPRL1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	67.29	28	24	53.3	0.93	4.7e-13	ABCG5 ABO APOB APOC2 ATP13A1 BCAM BUD13 C19orf80 DHX38 DOCK7 EPOR FNDC4 FUT2 HMGCR HP LDLR LRPPRC OPRL1 PAFAH1B2 PLEC PSRC1 PVRL2 RP11-288H12.3 SLC44A2 ST3GAL4 TOMM40 ZNF229 ZNF259
Triglycerides	53.46	14	9	20.0	0.77	1.2e-03	APOB APOC2 ATP13A1 BUD13 DOCK7 FNDC4 FUT2 HP LPL NAT2 PAFAH1B2 PVRL2 RP11-288H12.3 ZNF259
High cholesterol (Self-reported)	49.13	32	31	68.9	0.98	4.9e-23	ABCG5 ABO APOB APOC2 ATP13A1 BCAM BUD13 C19orf80 DHX38 DOCK7 EPOR FNDC4 FUT2 HMGCR HP LDLR LPL LRPPRC NAT2 OPRL1 PAFAH1B2 PLEC PSRC1 PVRL2 RP11-288H12.3 SLC22A1 SLC44A2 ST3GAL4 TMEM133 TOMM40 ZNF229 ZNF259
Medication: Simvastatin	25.15	31	22	48.9	0.99	1.2e-27	ABCG5 ABO APOB APOC2 ATP13A1 BCAM BUD13 C19orf80 DHX38 DOCK7 EPOR FES FNDC4 FUT2 HMGCR HP LDLR LPL LRPPRC NAT2 OPRL1 PAFAH1B2 PLEC PSRC1 PVRL2 SLC44A2 ST3GAL4 TMEM133 TOMM40 ZNF229 ZNF259
Cholesterol lowering medication	23.47	25	17	37.8	0.98	8.4e-19	ABCG5 ABO APOB APOC2 BCAM BUD13 C19orf80 DOCK7 EPOR FNDC4 FUT2 HMGCR HP LDLR LPL LRPPRC NAT2 OPRL1 PAFAH1B2 PSRC1 PVRL2 SLC22A1 TOMM40 ZNF229 ZNF259
Alzheimer’s Disease (including proxy)	21.34	5	5	11.1	0.92	2.6e-02	APOC2 BCAM PVRL2 TOMM40 ZNF229
Medication: Atorvastatin	21.28	24	11	24.4	0.98	4.7e-17	ABO APOB ATP13A1 BCAM BUD13 C19orf80 DHX38 DOCK7 EPOR FNDC4 FUT2 HMGCR HP LPL LRPPRC PAFAH1B2 PLEC PSRC1 PVRL2 SLC22A1 SLC44A2 TOMM40 ZNF229 ZNF259
HDL Cholesterol	16.74	8	3	6.7	-0.58	1.3e-01	APOB APOC2 BUD13 LPL PSRC1 PVRL2 TOMM40 ZNF259
Medication for cholesterol, blood pressure or diabetes	14.11	20	9	20.0	-0.95	3.3e-10	APOB BCAM BUD13 C19orf80 DHX38 EPOR FES FNDC4 FUT2 HMGCR HP LPL LRPPRC OPRL1 PAFAH1B2 PSRC1 SLC22A1 TMEM133 TOMM40 ZNF259
Cardiovascular Disease	12.58	25	21	46.7	0.92	9.7e-11	ABCG5 APOB BCAM BUD13 DHX38 DOCK7 EPOR FES FNDC4 FUT2 HMGCR HP LPL LRPPRC OPRL1 PAFAH1B2 PSRC1 PVRL2 RP11-288H12.3 SLC22A1 ST3GAL4 TMEM133 TOMM40 ZNF229 ZNF259
Alzheimer’s Disease (in mother)	12.10	5	5	11.1	0.95	1.3e-02	APOC2 BCAM PVRL2 TOMM40 ZNF229
Illnesses of father: Heart disease	8.56	9	4	8.9	0.91	7.4e-04	ABO EPOR FES LPL OPRL1 PSRC1 SLC22A1 SLC44A2 ST3GAL4
Coronary Artery Disease (CAD)	8.35	6	3	6.7	0.90	1.4e-02	BUD13 EPOR LPL PSRC1 ST3GAL4 ZNF259
Angina (self-reported)	7.91	9	4	8.9	0.95	1.1e-04	ABCG5 C19orf80 FES LPL OPRL1 PSRC1 RP11-288H12.3 SLC22A1 TMEM133
Angina	7.74	10	3	6.7	0.95	2.5e-05	ABCG5 APOC2 C19orf80 FES LPL OPRL1 PSRC1 RP11-288H12.3 SLC22A1 TMEM133
Medication: Aspirin	7.09	6	2	4.4	0.66	1.5e-01	EPOR FES LPL OPRL1 PSRC1 SLC22A1
Medication for cholesterol	6.85	11	2	4.4	-0.93	4.0e-05	DOCK7 FES FNDC4 FUT2 HMGCR HP LDLR PAFAH1B2 PSRC1 PVRL2 TMEM133
Medication: Aspirin	6.70	6	2	4.4	0.93	6.3e-03	C19orf80 FES LPL OPRL1 PSRC1 SLC22A1
Heart attack	6.23	6	4	8.9	0.90	1.4e-02	C19orf80 FES LPL PSRC1 RP11-288H12.3 SLC22A1
Heart attack/myocardial infarction (self-reported)	6.20	5	4	8.9	0.87	5.5e-02	FES LPL PSRC1 RP11-288H12.3 SLC22A1
Vascular/heart problems diagnosed by doctor	6.17	5	4	8.9	-0.39	5.1e-01	FES FUT2 NAT2 OPRL1 TMEM133
Systolic Blood Pressure	5.77	9	4	8.9	0.65	5.9e-02	EPOR FES FNDC4 FUT2 OPRL1 PAFAH1B2 ST3GAL4 TMEM133 TOMM40
Alzheimer’s Disease (in father)	5.66	4	2	4.4	0.96	3.6e-02	APOC2 PVRL2 TOMM40 ZNF229
Hypertension (Self-reported)	5.30	4	4	8.9	0.01	9.9e-01	FES FUT2 OPRL1 TMEM133
High blood pressure	5.14	4	3	6.7	0.08	9.2e-01	FES FUT2 OPRL1 TMEM133
Medication: Blood pressure	5.01	4	2	4.4	0.10	9.0e-01	FES FUT2 OPRL1 TMEM133
Blood Platelet Count	4.73	16	12	26.7	-0.09	7.3e-01	ABO APOC2 ATP13A1 BUD13 DOCK7 FNDC4 FUT2 HMGCR HP LPL PAFAH1B2 PLEC PVRL2 SLC44A2 TOMM40 ZNF259
Blood Red Count	4.66	7	6	13.3	-0.59	1.6e-01	ABCG5 ABO ATP13A1 FNDC4 HP PLEC PVRL2
Number of treatments/medications taken	4.65	6	2	4.4	0.53	2.8e-01	FES FNDC4 FUT2 LDLR PSRC1 TMEM133
Systolic blood pressure, automated reading	4.50	4	3	6.7	0.90	1.0e-01	FES OPRL1 ST3GAL4 TMEM133
Heart disease (mother)	4.50	1	1	2.2	0.00	1.0e+00	SLC22A1
Number of self-reported non-cancer illnesses	4.48	5	1	2.2	1.00	1.9e-04	DHX38 FNDC4 FUT2 OPRL1 TMEM133
Medication: Blood pressure	4.40	4	2	4.4	0.02	9.8e-01	FES FUT2 OPRL1 TMEM133
Illnesses of father: None of the above (group 1)	4.37	2	1	2.2	0.00	1.0e+00	FES SLC44A2
Gout (self-reported)	4.30	1	1	2.2	0.00	1.0e+00	FNDC4
Heart disease (siblings)	4.15	2	0	0.0	0.00	1.0e+00	FES SLC22A1
Medication: Atenolol	3.96	3	1	2.2	0.00	1.0e+00	FES PSRC1 TMEM133
Diastolic blood pressure, automated reading	3.93	5	2	4.4	0.63	2.5e-01	ABO C19orf80 FES FUT2 TMEM133
Fasting Glucose	3.81	1	1	2.2	0.00	1.0e+00	FNDC4
Blood clot in the leg (DVT)	3.73	2	1	2.2	0.00	1.0e+00	ABO SLC44A2
Medication: Ramipril	3.65	2	1	2.2	0.00	1.0e+00	FES TMEM133
Deep venous thrombosis (DVT) (self-reported)	3.56	2	1	2.2	0.00	1.0e+00	ABO SLC44A2
Medication: Allopurinol	3.51	1	1	2.2	0.00	1.0e+00	FNDC4
Alcohol intake frequency.	3.47	2	2	4.4	0.00	1.0e+00	FNDC4 FUT2
High blood pressure (mother)	3.34	2	1	2.2	0.00	1.0e+00	FES TMEM133
Father's age at death	3.30	3	1	2.2	0.00	1.0e+00	FES LPL PSRC1
Illnesses of mother	3.23	2	1	2.2	0.00	1.0e+00	FES TMEM133
Type 2 Diabetes (T2D) (2018)	3.07	3	1	2.2	0.00	1.0e+00	ATP13A1 FNDC4 LPL
Illnesses of siblings	3.04	3	1	2.2	0.00	1.0e+00	FES NAT2 TMEM133
Illnesses of father: High blood pressure	3.04	2	1	2.2	0.00	1.0e+00	FES TMEM133
Birth weight of first child	2.99	3	1	2.2	0.00	1.0e+00	ATP13A1 FES OPRL1
High blood pressure (siblings)	2.87	3	1	2.2	0.00	1.0e+00	FES FNDC4 TMEM133
Trunk fat-free mass	2.83	8	6	13.3	-0.68	6.5e-02	EPOR FNDC4 FUT2 HMGCR PLEC PSRC1 SLC44A2 TMEM133
Trunk predicted mass	2.81	8	6	13.3	-0.68	6.5e-02	EPOR FNDC4 FUT2 HMGCR PLEC PSRC1 SLC44A2 TMEM133
Arm fat-free mass (right)	2.74	7	4	8.9	-0.70	8.3e-02	EPOR FNDC4 FUT2 HMGCR PLEC PSRC1 SLC44A2
Medication: Amlodipine	2.69	2	2	4.4	0.00	1.0e+00	FES TMEM133
Whole body water mass	2.69	8	4	8.9	-0.55	1.6e-01	ATP13A1 EPOR FNDC4 HMGCR PLEC PSRC1 SLC44A2 TMEM133
Arm predicted mass (right)	2.68	7	4	8.9	-0.69	8.5e-02	EPOR FNDC4 FUT2 HMGCR PLEC PSRC1 SLC44A2
Whole body fat-free mass	2.68	8	5	11.1	-0.55	1.6e-01	ATP13A1 EPOR FNDC4 HMGCR PLEC PSRC1 SLC44A2 TMEM133
Arm predicted mass (left)	2.68	6	4	8.9	-0.71	1.1e-01	EPOR FNDC4 HMGCR PLEC PSRC1 SLC44A2
Pulse rate, automated reading	2.67	3	1	2.2	0.00	1.0e+00	APOB DHX38 FNDC4
Arm fat-free mass (left)	2.64	6	4	8.9	-0.69	1.3e-01	EPOR FNDC4 HMGCR PLEC PSRC1 SLC44A2
Basal metabolic rate	2.54	7	3	6.7	-0.57	1.8e-01	ATP13A1 EPOR FNDC4 HMGCR PLEC PSRC1 SLC44A2
Diabetes diagnosed by doctor	2.53	2	1	2.2	0.00	1.0e+00	ATP13A1 FNDC4
Diabetes (mother)	2.52	3	0	0.0	0.00	1.0e+00	ATP13A1 FNDC4 PVRL2
Leg fat-free mass (right)	2.50	8	4	8.9	-0.54	1.7e-01	ATP13A1 EPOR FES FNDC4 HMGCR PSRC1 SLC44A2 TMEM133
Leg predicted mass (right)	2.49	8	4	8.9	-0.54	1.7e-01	ATP13A1 EPOR FES FNDC4 HMGCR PSRC1 SLC44A2 TMEM133
Leg predicted mass (left)	2.48	7	4	8.9	-0.65	1.2e-01	ATP13A1 EPOR FES FNDC4 HMGCR SLC44A2 TMEM133
Leg fat-free mass (left)	2.47	7	4	8.9	-0.65	1.1e-01	ATP13A1 EPOR FES FNDC4 HMGCR SLC44A2 TMEM133
Blood White Count	2.46	8	4	8.9	-0.04	9.3e-01	ABO ATP13A1 DOCK7 FES FNDC4 PAFAH1B2 PVRL2 TMEM133
Alcohol intake versus 10 years previously	2.45	2	1	2.2	0.00	1.0e+00	FNDC4 FUT2
Medication: Metformin	2.40	3	1	2.2	0.00	1.0e+00	ABO FNDC4 LPL
Medication: Bendroflumethiazide	2.40	3	2	4.4	0.00	1.0e+00	FES FUT2 TMEM133
Diabetes (self-reported)	2.39	2	1	2.2	0.00	1.0e+00	ATP13A1 FNDC4
Crohns Disease (2017)	2.36	3	2	4.4	0.00	1.0e+00	DOCK7 FNDC4 FUT2
Pulse rate	2.29	2	1	2.2	0.00	1.0e+00	FNDC4 SLC22A1
Diabetes (father)	2.28	1	0	0.0	0.00	1.0e+00	FNDC4
Impedance of leg (left)	2.16	7	4	8.9	0.27	5.6e-01	ABO ATP13A1 FES FNDC4 HMGCR OPRL1 TMEM133
Weight	2.08	6	3	6.7	-0.47	3.5e-01	ATP13A1 EPOR FNDC4 HMGCR HP SLC44A2
Comparative height size at age 10	2.02	7	4	8.9	0.19	6.9e-01	ATP13A1 FES FNDC4 FUT2 PLEC PSRC1 SLC44A2
Impedance of leg (right)	1.99	7	4	8.9	0.33	4.7e-01	ABO ATP13A1 FES FNDC4 HMGCR OPRL1 TMEM133
Birth weight	1.96	2	1	2.2	0.00	1.0e+00	FES FUT2
Crohns Disease (2012)	1.94	3	1	2.2	0.00	1.0e+00	DOCK7 FNDC4 FUT2
Hip circumference	1.90	6	3	6.7	-0.59	2.2e-01	FNDC4 HMGCR HP OPRL1 SLC44A2 ST3GAL4
Medication: Lisinopril	1.89	1	0	0.0	0.00	1.0e+00	TMEM133
Ovarian Cancer	1.85	1	0	0.0	0.00	1.0e+00	ABO
Bipolar Disorder (2018)	1.84	2	0	0.0	0.00	1.0e+00	FNDC4 SLC44A2
Impedance of whole body	1.82	4	3	6.7	0.94	6.0e-02	FNDC4 HMGCR OPRL1 TMEM133
BMI	1.81	7	3	6.7	-0.26	5.7e-01	DHX38 FNDC4 HMGCR HP LPL OPRL1 ZNF229
Impedance of arm (left)	1.81	4	2	4.4	0.96	3.8e-02	ABO FNDC4 HMGCR OPRL1
Irritable Bowel Disease (IBD)	1.79	3	1	2.2	0.00	1.0e+00	FNDC4 FUT2 OPRL1
Relative age of first facial hair	1.78	1	1	2.2	0.00	1.0e+00	FNDC4
Standing height	1.77	10	5	11.1	-0.42	2.3e-01	ABCG5 APOC2 ATP13A1 EPOR FNDC4 FUT2 PLEC PSRC1 RP11-288H12.3 SLC44A2
Impedance of arm (right)	1.73	3	2	4.4	0.00	1.0e+00	FNDC4 HMGCR OPRL1
Height	1.70	17	11	24.4	-0.55	2.1e-02	ABCG5 ABO APOC2 ATP13A1 DHX38 EPOR FES FNDC4 FUT2 LPL PLEC PSRC1 RP11-288H12.3 SLC44A2 TMEM133 ZNF229 ZNF259
Arm fat mass (left)	1.70	5	1	2.2	-0.60	2.9e-01	FNDC4 HMGCR HP PVRL2 SLC44A2
Sitting height	1.69	8	3	6.7	-0.53	1.8e-01	ABCG5 ABO ATP13A1 FNDC4 FUT2 HP PLEC SLC44A2
Forced expiratory volume in 1-second (FEV1)	1.69	6	1	2.2	-0.71	1.2e-01	ABO DHX38 EPOR PVRL2 SLC44A2 TMEM133
Arm fat mass (right)	1.69	4	1	2.2	-0.58	4.2e-01	FNDC4 HMGCR HP PVRL2
Ever smoked	1.69	1	0	0.0	0.00	1.0e+00	FES
Rheumatoid Arthritis	1.68	1	0	0.0	0.00	1.0e+00	OPRL1
Waist Hip Ratio (WHR)	1.68	7	1	2.2	-0.14	7.6e-01	ATP13A1 FUT2 LPL LRPPRC OPRL1 PLEC SLC44A2
Serious illness, injury or assault of a close relative in last 2 years	1.67	1	0	0.0	0.00	1.0e+00	FUT2
Allergy	1.66	2	1	2.2	0.00	1.0e+00	ABO FES
Blood Eosinophil Count	1.65	12	5	11.1	-0.34	2.7e-01	ABO APOC2 BCAM BUD13 EPOR LPL OPRL1 PAFAH1B2 SLC44A2 ST3GAL4 TOMM40 ZNF259
Arm fat percentage (right)	1.60	5	1	2.2	-0.29	6.4e-01	ABO DHX38 HMGCR HP PVRL2
Pulse wave peak to peak time	1.59	1	0	0.0	0.00	1.0e+00	FES
Hand grip strength (left)	1.56	3	0	0.0	0.00	1.0e+00	DHX38 FES PVRL2
Body mass index (BMI)	1.56	5	1	2.2	-0.49	4.1e-01	DHX38 FNDC4 HMGCR HP PVRL2
Forced expiratory volume in 1-second (FEV1), Best measure	1.56	5	0	0.0	-0.61	2.7e-01	ABO EPOR PVRL2 SLC44A2 TMEM133
Bipolar Disorder or Schizophrenia	1.55	2	1	2.2	0.00	1.0e+00	FES FUT2
Forced vital capacity (FVC)	1.55	6	1	2.2	-0.70	1.2e-01	ABO DHX38 EPOR PVRL2 SLC44A2 TMEM133
Forced vital capacity (FVC), Best measure	1.55	6	0	0.0	-0.67	1.5e-01	ABO DHX38 EPOR PLEC PVRL2 SLC44A2
Mother's age at death	1.55	1	0	0.0	0.00	1.0e+00	SLC22A1
Hand grip strength (right)	1.54	3	0	0.0	0.00	1.0e+00	FNDC4 LRPPRC PVRL2
Arm fat percentage (left)	1.54	5	1	2.2	-0.32	6.0e-01	ABO DHX38 HMGCR HP PVRL2
Had other major operations	1.53	1	0	0.0	0.00	1.0e+00	ABCG5
Peak expiratory flow (PEF)	1.53	2	1	2.2	0.00	1.0e+00	ABO FUT2
Smoking Status	1.52	2	0	0.0	0.00	1.0e+00	DHX38 FES
Forced expiratory volume in 1-second (FEV1), predicted	1.52	2	0	0.0	0.00	1.0e+00	PLEC SLC44A2
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.52	2	0	0.0	0.00	1.0e+00	ABO PVRL2
Waist circumference	1.51	4	1	2.2	-0.61	3.9e-01	FNDC4 HMGCR HP PVRL2
Average weekly spirits intake	1.49	1	0	0.0	0.00	1.0e+00	FUT2
Had menopause	1.46	1	0	0.0	0.00	1.0e+00	LPL
Chronic bronchitis/emphysema (mother)	1.46	1	0	0.0	0.00	1.0e+00	BCAM
Leg fat mass (right)	1.45	5	1	2.2	-0.62	2.7e-01	BCAM FNDC4 HMGCR HP PVRL2
Leg fat mass (left)	1.45	4	1	2.2	-0.61	3.9e-01	BCAM FNDC4 HMGCR HP
Breast Cancer	1.44	3	0	0.0	0.00	1.0e+00	ABO FES OPRL1
Back pain experienced in last month	1.43	1	0	0.0	0.00	1.0e+00	APOB
HbA1C	1.42	1	0	0.0	0.00	1.0e+00	ABO
Whole body fat mass	1.42	4	1	2.2	-0.58	4.2e-01	BCAM HMGCR HP PVRL2
Risk taking	1.42	1	0	0.0	0.00	1.0e+00	FES
Mouth/teeth dental problems	1.40	1	0	0.0	0.00	1.0e+00	FUT2
Breastfed as a baby	1.40	1	0	0.0	0.00	1.0e+00	FES
Average weekly fortified wine intake	1.39	1	0	0.0	0.00	1.0e+00	PLEC
Mouth/teeth dental problems: Dentures	1.39	1	1	2.2	0.00	1.0e+00	FUT2
Trunk fat mass	1.38	5	1	2.2	-0.62	2.7e-01	BCAM HMGCR HP PVRL2 SLC44A2
Schizophrenia vs Biploar Disorder	1.37	1	0	0.0	0.00	1.0e+00	FNDC4
Hayfever, allergic rhinitis or eczema	1.36	1	0	0.0	0.00	1.0e+00	PVRL2
Schizophrenia (2018)	1.34	1	1	2.2	0.00	1.0e+00	FES
Lung FEV1/FVC ratio	1.34	4	3	6.7	0.61	3.9e-01	FUT2 NAT2 PSRC1 TMEM133
Allergy or Eczema	1.32	4	0	0.0	0.67	3.3e-01	ABO FES FNDC4 PVRL2
Mean time to correctly identify matches	1.30	2	0	0.0	0.00	1.0e+00	FES SLC44A2
Knee pain experienced in last month	1.29	1	0	0.0	0.00	1.0e+00	SLC44A2
Ulcerative Colitis (UC)	1.28	1	1	2.2	0.00	1.0e+00	OPRL1
Schizophrenia (2014)	1.26	1	1	2.2	0.00	1.0e+00	FES
Chronotype (morning person)	1.25	1	0	0.0	0.00	1.0e+00	SLC44A2
Number of operations (self-reported)	1.25	1	0	0.0	0.00	1.0e+00	ABCG5
Body fat percentage	1.21	4	1	2.2	-0.63	3.7e-01	BCAM HMGCR HP PVRL2
Sensitivity / hurt feelings	1.19	1	1	2.2	0.00	1.0e+00	FES
Asthma (self-reported)	1.18	1	0	0.0	0.00	1.0e+00	ABO
Lupus	1.17	1	0	0.0	0.00	1.0e+00	FUT2
Respiratory disease	1.17	2	0	0.0	0.00	1.0e+00	ABO FES
Trunk fat percentage	1.17	4	1	2.2	-0.63	3.7e-01	BCAM HMGCR HP PVRL2
Neck or shoulder pain in last month	1.15	1	0	0.0	0.00	1.0e+00	SLC44A2
Number of incorrect matches in round	1.14	2	0	0.0	0.00	1.0e+00	FES NAT2
Heel bone mineral density (BMD) T-score, automated (left)	1.13	2	0	0.0	0.00	1.0e+00	ABO TMEM133
Heel bone mineral density (BMD) T-score, automated (right)	1.13	2	0	0.0	0.00	1.0e+00	ABO TMEM133
Qualifications: nursing, teaching	1.12	1	0	0.0	0.00	1.0e+00	DOCK7
Headache pain in last month	1.11	1	0	0.0	0.00	1.0e+00	FES
Osteoarthritis (self-reported)	1.11	1	0	0.0	0.00	1.0e+00	SLC44A2
Leg fat percentage (left)	1.11	2	1	2.2	0.00	1.0e+00	BCAM HMGCR
Worry (Nagel 2018)	1.10	1	0	0.0	0.00	1.0e+00	SLC22A1
Leg fat percentage (right)	1.10	3	1	2.2	0.00	1.0e+00	BCAM HMGCR HP
Heel T-Score	1.08	5	2	4.4	-0.79	1.1e-01	ABO ATP13A1 HMGCR PSRC1 TMEM133
Alcohol usually taken with meals	1.08	1	0	0.0	0.00	1.0e+00	FES
Lung FVC	1.07	4	2	4.4	-0.45	5.5e-01	ABO FNDC4 OPRL1 PVRL2
Reaction Time	1.02	1	0	0.0	0.00	1.0e+00	SLC44A2
Handedness (chirality/laterality): Left-handed	1.02	1	0	0.0	0.00	1.0e+00	FES
Hypothyroidism (self reported)	1.00	1	0	0.0	0.00	1.0e+00	FUT2
Comparative body size at age 10	0.96	1	0	0.0	0.00	1.0e+00	FUT2
Irritability	0.91	1	0	0.0	0.00	1.0e+00	ATP13A1
Hair/balding pattern: Pattern 4	0.90	2	0	0.0	0.00	1.0e+00	FES NAT2
Qualifications: College or University degree	0.89	1	0	0.0	0.00	1.0e+00	BUD13
Qualifications: None of the above	0.88	1	0	0.0	0.00	1.0e+00	DOCK7
Age when periods started (menarche)	0.85	1	0	0.0	0.00	1.0e+00	FUT2
Neuroticism	0.84	1	0	0.0	0.00	1.0e+00	SLC22A1
Neuroticism (Nagel 2018)	0.81	1	0	0.0	0.00	1.0e+00	SLC22A1
Tanning	0.37	4	1	2.2	-0.55	4.5e-01	DHX38 EPOR FNDC4 PLEC
Hair Pigment	0.26	7	2	4.4	0.37	4.2e-01	DHX38 EPOR FES FNDC4 OPRL1 SLC44A2 TMEM133

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	2.0
GTEx	Liver	2	0.279	1.9
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.7
GTEx	Esophagus Mucosa	9	0.271	1.7
GTEx	Vagina	1	0.157	1.7
GTEx	Whole Blood	5	0.251	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	7	0.339	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	4	0.195	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	5	0.297	1.7
GTEx	Adrenal Gland	0	0.000	1.6
GTEx	Artery Aorta	3	0.101	1.6
GTEx	Artery Tibial	6	0.160	1.6
GTEx	Brain Cerebellum	1	0.050	1.6
GTEx	Brain Cortex	0	0.000	1.6
GTEx	Brain Frontal Cortex BA9	0	0.000	1.6
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.6
GTEx	Cells Transformed fibroblasts	7	0.167	1.6
GTEx	Esophagus Muscularis	4	0.124	1.6
GTEx	Muscle Skeletal	4	0.138	1.6
GTEx	Ovary	1	0.110	1.6
GTEx	Pituitary	2	0.179	1.6
GTEx	Prostate	1	0.120	1.6
GTEx	Skin Sun Exposed Lower leg	5	0.137	1.6
GTEx	Small Intestine Terminal Ileum	0	0.000	1.6
GTEx	Stomach	2	0.138	1.6
GTEx	Thyroid	5	0.125	1.6
NTR	Blood	4	0.167	1.6
ROSMAP	Brain Pre-frontal Cortex	7	0.159	1.6
YFS	Blood	6	0.130	1.6
CommonMind	Brain Pre-frontal Cortex	7	0.130	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	8	0.195	1.6
The Cancer Genome Atlas	Lung Adenocarcinoma	3	0.102	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	5	0.314	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	1.6
GTEx	Adipose Subcutaneous	1	0.029	1.5
GTEx	Adipose Visceral Omentum	2	0.098	1.5
GTEx	Artery Coronary	0	0.000	1.5
GTEx	Brain Hypothalamus	0	0.000	1.5
GTEx	Breast Mammary Tissue	0	0.000	1.5
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.5
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.5
GTEx	Colon Sigmoid	2	0.137	1.5
GTEx	Colon Transverse	0	0.000	1.5
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.5
GTEx	Heart Atrial Appendage	0	0.000	1.5
GTEx	Lung	1	0.035	1.5
GTEx	Nerve Tibial	2	0.046	1.5
GTEx	Pancreas	2	0.123	1.5
GTEx	Skin Not Sun Exposed Suprapubic	4	0.163	1.5
GTEx	Spleen	3	0.213	1.5
GTEx	Testis	3	0.095	1.5
METSIM	Adipose	3	0.065	1.5
The Cancer Genome Atlas	Breast Invasive Carcinoma	6	0.136	1.5
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	3	0.110	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	7	0.163	1.5
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	4	0.160	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	11	0.238	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	9	0.174	1.5
GTEx	Brain Hippocampus	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.4
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Uterus	0	0.000	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.3